HC Wainwright Reaffirms “Neutral” Rating for Predictive Oncology (NASDAQ:POAI)

HC Wainwright reissued their neutral rating on shares of Predictive Oncology (NASDAQ:POAI) in a report issued on Friday, Marketbeat reports. HC Wainwright also issued estimates for Predictive Oncology’s Q4 2025 earnings at $0.06 EPS, FY2026 earnings at $0.08 EPS, FY2027 earnings at $0.27 EPS and FY2028 earnings at $0.46 EPS.

Predictive Oncology Price Performance

Shares of NASDAQ:POAI traded down $0.05 during trading hours on Friday, hitting $0.69. 145,775 shares of the company’s stock traded hands, compared to its average volume of 1,323,487. The business has a fifty day moving average price of $0.75 and a 200-day moving average price of $1.07. Predictive Oncology has a 1 year low of $0.55 and a 1 year high of $3.76. The firm has a market capitalization of $4.58 million, a P/E ratio of -0.23 and a beta of 1.14.

Predictive Oncology (NASDAQ:POAI) last announced its quarterly earnings data on Tuesday, August 13th. The medical instruments supplier reported ($0.68) earnings per share for the quarter. Predictive Oncology had a negative net margin of 1,012.32% and a negative return on equity of 286.30%. The company had revenue of $0.28 million for the quarter. As a group, equities analysts predict that Predictive Oncology will post -2.03 earnings per share for the current year.

Predictive Oncology Company Profile

Predictive Oncology Inc operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples.